US Food and Drug Administration has given its clearance to the Cadila Healthcare's facilities at Moraiya after it had issued a warning letter in June 2011 over non-conformity of norms.

The company informed the stock exchanges n filing that the warning letter has been revoked by the US FDA. The US watchdog had issued the warning letter it was concerned that the non-conformity with its laws would mean that the company's could be adulterated.

"We are concerned that trained microbiologists employed by your firm were unable to accurately identify microbial growth on environmental monitoring plates. Additionally, there is no assurance that such errors have not occurred previously," the warning letter had read.

The authority was concerned over keeping the area completely sterile. The letter had warned that the company might face a ban on the products manufactured at the plant and will not be allowed to sell the products in the US.

After reports suggested that the letter has been revoked, the shares of the pharmaceutical company rose more than 4 percent and were trading at around Rs 830 on the Bombay Stock Exchange (BSE) at the time of reporting this morning.